Showing results (431-440 of 520) with videos related to
Sort By:
Pageof 52
Cell & Bioscience|June 18, 2025
Generation of a spontaneous murine HPV + oral cancer model with site-specific oncogene insertion using CRISPR-SONICJulia Tao, Jason Murray, Hsin-Fang Tu, et al.Oncogene|July 8, 2014
FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reductionD-W Wu, M-C Lee, N-Y Hsu, et al.Cell & Bioscience|December 25, 2024
Improved efficacy of therapeutic HPV DNA vaccine using intramuscular injection with electroporation compared to conventional needle and needle-free jet injector methodsShiwen Peng, Darrell Fan, Hsin-Fang Tu, et al.Cell & Bioscience|March 6, 2014
Control of HPV-associated tumors by innovative therapeutic HPV DNA vaccine in the absence of CD4+ T cellsShiwen Peng, Liwen Song, Jayne Knoff, et al.Cancer Immunology, Immunotherapy : CII|October 27, 2020
PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical modelShiwen Peng, Marietta Tan, Yen-Der Li, et al.Oncogene|July 17, 2015
FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reductionD-W Wu, M-C Lee, N-Y Hsu, et al.Journal of Biomedical Science|August 12, 2022
Localization of Salmonella and albumin-IL-2 to the tumor microenvironment augments anticancer T cell immunityYu-Jui Kung, Brandon Lam, Ssu-Hsueh Tseng, et al.The American Journal of Pathology|March 1, 1992
Demonstration of cytomegalovirus nucleic acids in the coronary arteries of transplanted heartsT C Wu, R H Hruban, R F Ambinder, et al.Oncogene|July 18, 2017
FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reductionD-W Wu, M-C Lee, N-Y Hsu, et al.Annals of Internal Medicine|December 1, 1981
A cluster of Acinetobacter Pneumonia in foundry workersL G Cordes, E W Brink, P J Checko, et al.Pageof 52